Biomarin Pharmaceutical
Open
$55.94
Prev. Close
$56.00
High
$56.01
Low
$55.90
Market Snapshot
$10.76B
40.0
2.25
$2.85B
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,221 full-time employees. The firm has a portfolio of commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its Galafold (migalastat) is the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), is a two-component therapy for Pompe disease.
Recently from Cashu
BioMarin Pharmaceutical's VOXZOGO Shows Promise in Rare Disease Treatment and Strategic Partnerships
BioMarin Pharmaceutical (Ticker: BMRN) announces promising results from its Phase 3 clinical trials for VOXZOGO, a treatment designed for children with hypochondroplasia, a rare form of skeletal dyspl…
BioMarin's BMN 401 Trial Shows Biomarker Success but Lacks Clinical Benefits for ENPP1 Deficiency
BioMarin Pharmaceutical Inc. has made significant strides in addressing rare genetic disorders through its innovative research and clinical trials. The company recently provided an update on its Phase…
BioMarin Pharmaceutical's BMN 401 Trial Faces Setbacks in Treating ENPP1 Deficiency
BioMarin Pharmaceutical (Ticker: BMRN) faces both opportunities and challenges as it navigates the complexities of developing treatments for rare genetic disorders. The recent update on its Phase 3 EN…
BioMarin Advances VOXZOGO Treatment for Achondroplasia with Promising Clinical Trial Results
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced significant advancements regarding its treatment for achondroplasia, VOXZOGO® (vosoritide), which has become the sole approved therapy for chi…